Compare EFR & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EFR | CERS |
|---|---|---|
| Founded | N/A | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | EDP Services |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 333.9M | 276.0M |
| IPO Year | 2003 | 1996 |
| Metric | EFR | CERS |
|---|---|---|
| Price | $10.65 | $2.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 108.6K | ★ 1.1M |
| Earning Date | 01-01-0001 | 04-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.62 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $51,326,000.00 |
| Revenue This Year | N/A | $25.31 |
| Revenue Next Year | N/A | $9.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $10.40 | $1.12 |
| 52 Week High | $12.88 | $2.96 |
| Indicator | EFR | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 20.34 | 58.68 |
| Support Level | N/A | $1.99 |
| Resistance Level | $11.20 | $2.96 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 5.66 | 84.35 |
Eaton Vance Senior Floating Rate Trust is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income. As a secondary objective, the fund intends to seek capital preservation. Its portfolio of investments consists of Software, Health Care Providers & Services, Machinery, Chemicals, Professional Services, IT Services, Hotels, Restaurants & Leisure, Capital Markets, Specialty Retail, Commercial Services & Supplies, and other areas. The trust invests in below investment grade floating rate loans, which are considered speculative because of the credit risk of their issuers.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.